在骨关节炎中全关节整形术后,他类药物和修复手术的长期风险:一项多来源数据链接研究
Andrea D'Amuri1, Barbara Bordini2, Mauro Pagani1
1Unit of Internal Medicine, Azienda Ospedaliera Carlo Poma, Mantova, Italy.
Frontiers in pharmacology
|April 30, 2025
概括
在患有关节骨关节炎 (OA) 的患者中,术前使用他类药物与关节全整形术 (THA) 的风险降低有关. 这种保护作用在各种类型和适用于不同类型的他类药物中一致观察到,特别是在男性患者中.
科学领域:
- 整形外科 整形外科 整形外科
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 众所周知的降脂作用的他类药物表现出性作用,包括对骨代谢的潜在影响.
- 观察性研究表明,他类药物可能会降低骨折率.
- 类药物对关节全整形术 (THA) 失败的影响尚不清楚.
研究的目的:
- 调查手术前使用他类药物与关节炎 (OA) 患者THA修订风险之间的关联.
主要方法:
- 使用意大利RIPO注册表对接受OATHA的患者进行了回顾性分析.
- 倾向性得分 (PS) 匹配用于创建可比的他类药物使用者 (SU) 和非使用者 (SNU) 组.
- 组间对THA存活率进行了比较,二次分析探讨了死亡率,性别,适应症和他类药物特征.
主要成果:
- 分析了10,927名患者,在15年内,SU显示THA修订风险显著降低 (adjHR 0.76).
- 这种降低的风险在不同的他类药物指示和类型中是一致的.
- 在男性患者中,保护作用更为明显 (adjHR 0.64).
结论:
- 手术前使用他类药物治疗与关节骨髓炎患者THA修订的长期风险降低有关.
- 这种好处似乎独立于他类药物处方的原因.
- 进一步的研究可能会阐明这种保护性关联背后的具体机制.
更多相关视频
09:51The Transition to an Anterior-Based Muscle Sparing Approach Improves Early Postoperative Function but is Associated with a Learning Curve
Published on: September 7, 2022
2.5K
05:30Surgical Approach and Complications of Stand-alone Lateral Trans-Psoas Interbody Fusion
Published on: February 14, 2025
678
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
